Compounds > cladribine
Page last updated: 2024-08-22

cladribine and Adverse Drug Event

cladribine has been researched along with Adverse Drug Event in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Ferrè, L; Filippi, M; Martinelli, V; Meani, A; Moiola, L; Rocca, MA; Zanetta, C1
Mitsikostas, DD; Papadopoulos, D1
Comi, G; Cook, S; Galazka, A; Giovannoni, G; Hicking, C; Leist, T; Montalban, X; Nolting, A; Sylvester, E1
Drake, MT; Fishkin, PA; Inwards, DJ; Kurtin, PJ; Lair, BS; LaPlant, BR; Nikcevich, DA; Wender, DB; Witzig, TE1
Costello, K; Sipe, JC1
Graham-Rowe, D1

Reviews

1 review(s) available for cladribine and Adverse Drug Event

ArticleYear
Cladribine tablets' potential in multiple: sclerosis treatment.
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2008, Volume: 40, Issue:5

    Topics: Administration, Oral; Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting

2008

Trials

1 trial(s) available for cladribine and Adverse Drug Event

ArticleYear
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Rituximab; Sirolimus

2014

Other Studies

7 other study(ies) available for cladribine and Adverse Drug Event

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
    PLoS computational biology, 2011, Volume: 7, Issue:12

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Journal of neurology, 2023, Volume: 270, Issue:7

    Topics: Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence

2023
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
    CNS drugs, 2018, Volume: 32, Issue:11

    Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult

2018
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Multiple sclerosis and related disorders, 2019, Volume: 29

    Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Registries; Young Adult

2019
Drugs: An injection of hope.
    Nature, 2012, Apr-12, Volume: 484, Issue:7393

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration

2012